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ABSTRACT
Iodide inhibition was considered to be the key biochemical event preceding disruption of thyroid hormone homeostasis. The RfD was based on the No Observable Effect Level (NOEL) of 0.007 mg/kg-day, which resulted in no significant iodide inhibition in normal adults. An uncertainty factor of 10 was applied to the NOEL to account for intraspecies variability, including life-stage specific susceptibility. Recently, existing physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) models across life-stages in rat and in adult human were expanded to describe inhibition kinetics during perinatal development in humans. Chemical-specific parameters were estimated from life-stage and species-specific relationships established in previously published PBPK/PD models. The human perinatal models successfully simulate literature radioiodide data for gestation and lactation, as well as data from populations exposed to perchlorate contaminated drinking water. These validated models were used to examine the effect of developmental stage on susceptibility to thyroid perturbation across a range of doses. At environmentally relevant doses, the perinatal woman, fetus and nursing infant are predicted to have higher blood perchlorate concentrations and greater thyroid iodide uptake inhibition than either the non-pregnant adult or older child. At exposure levels equal to the NOEL and RfD, the PBPK/PD model predicted iodide inhibition in fetuses is within normal variation (less than 10%) and insignificant (less than 1%), respectively, indicating that the newly adopted RfD is in fact protective of the population most sensitive to thyroid inhibition. adults. An uncertainty factor of 10 was applied to the NOEL to account for intraspecies variability, including life-stage specific susceptibility. Recently, existing physiologically based pharmacokinetic/ pharnacodynamic (PBPK/PD) models across life-stages in rat and in adult human were expanded to describe inhibition kinetics during perinatal development in humans. Chemical-specific parameters were estimated from life-stage and species-specific relationships established in previously published PBPK/PD models. T'he human perinatal models successfully simulate literature radioiodide data for gestation and lactation, as well as data from populations exposed to perchlorate contaminated drinking water. These validated models were used to examine the effect of developmental stage on susceptibility to thyroid perturbation across a range of doses. At environmentally relevant doses, the perinatal woman, fetus and nursing infant are predicted to have higher blood perchlorate concentrations and greater thyroid iodide uptake inhibition than either the non-pregnant adult or older child. At exposure levels equal to the NOEL and RfD, the PBPK/PD model predicted iodide inhibition in fetuses is within normal variation (less than 10%) and insignificant (less than 1%), respectively, indicating that the newly adopted RfD is in fact protective of the population most sensitive to thyroid inhibition.
SUBJECT TERMS
INTRODUCTION
" Ammonium perchlorate is a key component of solid rocket fuel and has been found in the drinking water of 30+ states.
" The DoD, EPA, DOE and NASA asked the National Research Council (NRC) to address key scientific issues associated with perchlorate. " The NRC Committee on the Health Implications of Perchlorate Ingestion consisted of 15 national experts. Their final report concluded (NRC, 2005) : o Iodide uptake inhibition by perchlorate is the key biochemical event preceding disruption of thyroid hormone homeostasis. o A reduction of thyroid iodide uptake of at least 75% for a sustained period (several months or longer) would be required to decrease thyroid hormone production sufficiently to cause adverse health effects. o A reference dose (RfD), protective for all populations, could be established at 0.0007 mg/kg-day based on:
"* A NOEL of 0.007 mg/kg-day in a human perchlorate study (Greer et al., 2002) "* An uncertainty factor of 10 for intraspecies variability, including life stage specific susceptibility. In pregnant women, infants and children, and people who have a low iodide intake or pre-existing thyroid dysfunction, the dose required to cause a decrease in thyroid hormone production may be lower than in the normal population. o "A dose that does not inhibit thyroid iodide uptake will not affect thyroid function, even in subjects with an abnormal thyroid gland or a very low iodide intake" (NRC, 2005) * Iodide inhibition is a precursor to changes in hormone production, which in turn, is a precursor to adverse effects.
" The U.S. Environmental Protection Agency accepted the recommendation of the NRC Committee and entered a perchlorate RfD of 0.0007 mg/kg-day into their Integrated Risk Information System (IRIS).
Perchlorate PBPK/PD Models "* Using PBPK models, we can account for kinetic and physiological differences across life stages and quantitatively predict exposure and effect (thyroid inhibition) in the sensitive populations.
"* PBPK models of perchlorate and iodide were published for the adult human, as well as the adult male pregnant and lactating female, fetal and neonatal rat (Clewell et al., 2003a (Clewell et al., , 2003b Merrill et al., 2003; 2005a) .
"* Recently, these PBPK models were expanded to describe inhibition kinetics across life stages in the human, including the pregnant and lactating woman, fetal development and the child from birth to adulthood.
HUMAN LIFE-STAGE MODEL DEVELOPMENT "* Physiological Parameters: Based on published data and published PBPK models for human gestation, lactation and childhood (Gentry et al., 2002 , Clewell et al., 2004 "* Chemical-specific Parameters: Estimated from life-stage and species-specific relationships established in published PBPK/PD models (Clewell et aL, 2003a (Clewell et aL, , 2003b Merrill et al., 2003 Merrill et al., , 2005a " 
APPLICATION OF LIFE STAGE MODELS TO RISK ASSESSMENT
Determining Sensitive Population (Life-Stage): o Susceptibility to chemical effect may be due to differences in exposure, pharmacokinetics or pharmacodynamics o Models allow testing of the effects of different exposures (Figure 4 ) and pharmacokinetics ( Figure 5 ) on the endpoint of interest o Two ways to estimate susceptibility: Serum perchlorate AUC (area under the curve) and inhibition of thyroid uptake (% inhibition) o From predicted serum levels, the fetus is the most susceptible population based on pharmacokinetic and exposure differences ( Figure 5 ) "o Models were run at constant water concentration (RfD: 25 ppb), assuming daily water intake for the 9 5 h percentile (U.S. EPA, 1997 EPA, , 2002 . "o Simulations performed across time-points in gestation, lactation, childhood and in the adult "o Serum C10 4 AUC and % inhibition of thyroid were compared to determine most pharmacokinetically susceptible life-stage based on internal dose and estimated precursor effect Figure 4 . Serum perchlorate in breast-fed (yellow) vs. bottle-fed (orange) infant and the older child. Simulations in the breast-fed infant were performed at daily maternal water intake of 2 L (95th percentile for adults); the infant was exposed via maternal milk only. Simulations in the bottle-fed infant and in the older child assume daily water intake at 95th percentile for their age (1 L for <1 year of age). Perchlorate exposure for both simulations is assumed to occur exclusively through drinking water at a concentration of 25 ppb. .,OO Figure 5 . Serum perchlorate in the adult (purple), fetus (pink), breast-fed infant (yellow), bottle-fed infant (orange) and older child (yellow-orange). The dashed line is provided for comparison with the adult AUC. Simulations in adults, fetus (gestation week 38) and breast-fed infant (post-natal month 1) were performed at daily maternal water intake of 2 L (95t percentile for adults). Simulations in the bottle-fed infant (post-natal week 2) and older child (7 years) assume daily water intake at 95th percentile for their age. Perchlorate exposure for all simulations is assumed to occur exclusively through drinking water at a concentration of 25 ppb.
Estimating Risk Using PBPK Models: "o The most significant use of these models for risk assessment is the quantitative prediction of biological effect from perchlorate exposure. "o Based on NRC and EPA recommendations, preventing inhibition of iodide uptake in the thyroid will prevent downstream endocrine effects. "o The models can be used to determine a 'safe' perchlorate dose, below which thyroid inhibition is considered insignificant. o Because there are different concepts of 'insignificant inhibition', the model was run for several levels of inhibition, and the daily dose needed to reach the prescribed % inhibition was recorded across life-stages. 
CONCLUSIONS
"* PBPK models help bridge gaps between animal data and potential risk to humans at various life stages. o Using models that have been validated across life-stages in both the rat and human, we can predict safe exposure levels with more confidence and less uncertainty. "* At environmentally relevant doses, the perinatal woman, fetus and nursing infant are predicted to have higher blood perchlorate concentrations and greater thyroid iodide uptake inhibition than either the non-pregnant adult or older child. "* The models indicate that the fetus receives the greatest perchlorate dose (per kg BW) and is most susceptible to iodide inhibition at low doses. "* The model predicted daily dose estimated to disrupt thyroid hormone homeostasis in a normal adult (75% iodide inhibition (NRC, 2005) ) is 0.7 mg/kg-day from model predictions. o The NRC estimated this dose would be more than 0.4 mg/kg-day perchlorate for a 70-kg adult, based on clinical studies (Gibbs et al., 1998; Lamm et al., 1999; Crump et al., 2000) . "* Human exposure at the IRIS NOEL is predicted to result in 9% or less iodide inhibition across life stages. o Normal human variation in iodide uptake was measured at approximately 10% (Greer et aL, 2002) . "* Human exposure at the RfD is predicted to result in insignificant (less than 1%) iodide inhibition across life stages. "• The life stage models predict iodide inhibition levels for both fetus and neonate that support the protectiveness of the RfD.
